Final Program

122 SUNDAY • MAY 15
A103
POSTER DISCUSSION SESSION
IPF: MORE ABOUT THERAPY AND OUTCOMES
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 304 (South Building, Esplanade Level)
Poster Viewing 2:15-3:00
Discussion 3:00-4:15
Chairing: P.J. Sime, MD, Rochester, NY
C.J. Ryerson, MD, Vancouver, Canada
201 Antiacid Therapy and Disease Progression in Patients with
Idiopathic Pulmonary Fibrosis (IPF) Under Pirfenidone
Treatment/M. Kreuter, P. Spagnolo, W. Wuyts, E. Renzoni, D.
Koschel, T.M. Maher, M. Kolb, D. Weycker, K.-U. Kirchgaessler, U.
Costabel, Heidelberg, Germany, p.A2689
202 Efficacy of Nintedanib on Acute Exacerbations Reported as
Serious Adverse Events in the INPULSISr Trials in Idiopathic
Pulmonary Fibrosis (IPF)/M. Kreuter, H. Koegler, M. Trampisch,
S. Geier, L. Richeldi, Heidelberg, Germany, p.A2690
203 Effect of Baseline GAP Index Stage on Decline in Lung
Function with Nintedanib in Patients with Idiopathic
Pulmonary Fibrosis (IPF)/C.J. Ryerson, M. Kolb, L. Richeldi, J.
Lee, T. Kimura, S. Stowasser, V. Poletti, Vancouver, Canada,
p.A2691
204 Safety and Tolerability of Nintedanib in Patients with Idiopathic
Pulmonary Fibrosis (IPF): One-Year Data from Post-Marketing
Surveillance in the United States/I. Noth, A. Allinger, M. Kaul,
C.S. Conoscenti, D. Oelberg, Chicago, IL, p.A2692
205 Effect of Nintedanib on Disease Progression in the INPULSISr
Trials in Patients with Idiopathic Pulmonary Fibrosis (IPF)/G.
Raghu, Y. Inoue, J. Behr, V. Cottin, S. Stowasser, W. Stansen,
T.M. Maher, Seattle, WA, p.A2693
206 Efficay of Pirfenidone for Acute Exacerbation of Idiopathic
Pulmonary Fibrosis/K. Furuya, S. Sakamoto, H. Shimizu, M.
Sekiya, A. Kinoshita, T. Isshiki, K. Sugino, S. Homma, Tokyoto,
Japan, p.A2694
207 Safety of Pirfenidone in Patients with Idiopathic Pulmonary
Fibrosis in a US Expanded Access Program/L. Lancaster, L.
Morrison, A. Auais, B. Ding, A. Iqbal, K. Flaherty, Nashville, TN,
p.A2695
208 Effect of Pirfenidone on Cough in Patients with Idiopathic
Pulmonary Fibrosis/M.J.G. Van Manen, S.S. Birring, C. Vancheri,
V. Vindigni, M. Wapenaar, V. Cottin, M.S. Wijsenbeek, Rotterdam,
Netherlands, p.A2696
209 Treatment Destiny in Idiopathic Pulmonary Fibrosis Patients
Following Approval of Two Drug Therapies/M.L. Salisbury, M.
Xia, S. Murray, E.A. Belloli, R.A. Beckford, J.S. Sheth, E.S. White,
K.R. Flaherty, Ann Arbor, MI, p.A2697
210 PROOF: A Prospective Observational Registry to Describe the
Disease Course and Outcomes of Idiopathic Pulmonary
Fibrosis Patients in a Real-World Clinical Setting.
PROOF-Registry Belgium - Luxembourg: Comorbidities in 175
IPF Patients at Inclusion/W. Wuyts, B. Bondue, C. Dahlqvist, H.
Slabbynck, M. Schlesser, K. Richir, C. Compere, N. Gusbin, G.
Joos, Leuven, Belgium, p.A2698
211 Sarc-IPF: Combined Sarcoidosis and Idiopathic Pulmonary
Fibrosis; “Sarc-IPF”-A Distinct Clinical Entity or
Phenotype/B.F. Collins, L. Ho, J. Hayes, C. Spada, G. Raghu,
Seattle, WA, p.A2699
212 Two Agents for Idiopathic Pulmonary Fibrosis: Which One to
Choose?/S. Daouk, A. Aljaafareh, I. Faruqi, Gainesville, FL,
p.A2700
213 Favorable Human Safety, Pharmacokinetics and
Pharmacodynamics of the Autotaxin Inhibitor GLPG1690, a
Potential New Treatment in Idiopathic Pulmonary Fibrosis/E.M.
Van Der Aar, L. Fagard, J. Desrivot, S. Dupont, B. Heckmann, R.
Blanque, L. Gheyle, J. Ralic, F. Vanhoutte, Mechelen, Belgium,
p.A2701
214 Peripheral Blood Myeloid-Derived Suppressor Cells Reflect
Disease Status in IPF/I.E. Fernandez, F. Greiffo, M.
Frankenberger, K. Heinzelmann, C. Neurohr, R. Hatz, J. Behr, O.
Eickelberg, Munich, Germany, p.A2702
215 Effect of Nintedanib on Decline in Forced Vital Capacity (FVC)
over Time in the INPULSISr Trials in Patients with Idiopathic
Pulmonary Fibrosis/T.M. Maher, K.R. Flaherty, A. Azuma, V.
Cottin, W. Stansen, M. Quaresma, A. Wells, London, United
Kingdom, p.A2703
216 Comparison of the GAP Index and Staging System with the
Japanese Severity Classification System in Patients with
Idiopathic Pulmonary Fibrosis/M. Bando, Y. Sugiyama, A.
Azuma, M. Ebina, H. Taniguchi, Y. Taguchi, H. Takahashi, S.
Homma, Shimotsuke, Japan, p.A2704
217 Cumulative Distribution of Patients by Change in FVC %
Predicted in the INPULSISr Trials of Nintedanib in Patients
with Idiopathic Pulmonary Fibrosis/K.R. Flaherty, K.K. Brown, U.
Costabel, W. Stansen, R. Schlenker-Herceg, G. Raghu, Ann Arbor,
MI, p.A2705
218 Prediction of IPF with the Early Changes in Quantitative
Imaging Patterns Using High Resolution Computed
Tomography/G.H. Kim, M. Brown, S. Weigt, J.A. Belperio, J.
Goldin, Los Angeles, CA, p.A2706
219 Serum Anti-Myxovirus Resistance Protein-1 Autoantibody; a
Possible Novel Biomarker for Disease Severity and Prognosis
of Idiopathic Pulmonary Fibrosis/T. Arai, H. Kida, Y. Hamano, M.
Hirose, A. Murakami, T. Kagawa, A. Matsumuro, T. Koba, C.
Sugimoto, M. Akira, M. Kitaichi, S. Ihara, A. Kumanogoh, Y. Inoue,
Sakai, Japan, p.A2707
220 High Resolution CT Scan Pattern as a Predictor of Disease
Progression and Survival in Idiopathic Pulmonary Fibrosis/R.
Sharif, T. Kulkarni, P. Acosta-Lara, J.R. Watts, S.K. Sonavane, V.J.
Thannickal, T. Luckhardt, J.A. De Andrade, Birmingham, AL, p.A2708
ATS 2016 • San Francisco